← Back to Search
Peroxiredoxins In Colorectal Neoplasms.
X. Wu, Z. Fu, X. Wang
Published 2010 · Biology, Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Peroxiredoxins (Prxs) are novel group proteins with efficient antioxidant capacity, and some of them also have effects on cell proliferation, differentiation, apoptosis, and chemotherapy and radiotherapy resistance. Altogether six distinct Prxs expressions were investigated in histological samples of colorectal neoplasm and the distant normal tissues and investigated associatedly with parameters such as clinical stage and lymphnodes metastasis. Normal colorectal tissues were almost negative for Prxs, except Prx4 (15/32). In colorectal cancer tissues, the most prominent reactivity was observed with Prx2 in 23/32 cases, while the corresponding figures for others was 21/32 (Prx1), 18/32 (Prx3, Prx5, Prx6) and 8/32 (Prx4). Prx1 (P=0.023), Prx2 (P=0.012), and Prx5 (P=0.028) were the isoforms that showed significantly increased expression in colorectal cancer patients with stage III or lymphnodes metastasis-positive cases. There was a significant relationship between the expression of Prx1 and Prx2 (rs=0.425, P=0.015) and between Prx3 and Prx4 (rs=0.364, P=0.041). Additionally, 8 cases were studied by western analysis. Prx1, 2, 3, 5 and 6 were particularly elevated in tumors compared to nonmalignant tissue as assessed by immunohistochemistry. It appeared that some Prxs were upexpression in colorectal cancer tissues and may have some prognostic significance; the induction of Prxs could be explained by increased production of reactive oxygen species in carcinomatous tissue.
This paper references
Antioxidant defenses in the lung.
I. Fridovich (1986)
Increased risk of large-bowel cancer in Crohn's disease with colonic involvement
A. Ekbom (1990)
Strategies of antioxidant defense
H. Sies (1993)
Cloning, sequencing, and mutation of thiol-specific antioxidant gene of Saccharomyces cerevisiae.
H. Z. Chae (1993)
Cloning , sequencing , and mutation of thiolspecific antioxidant gene of Saccharomyces cerevisiae
Z. ChaeH. (1993)
On the protective mechanism of the thiol-specific antioxidant enzyme against the oxidative damage of biomacromolecules.
M. B. Yim (1994)
Thioredoxin-dependent peroxide reductase from yeast.
H. Z. Chae (1994)
Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation.
D. Y. Jin (1997)
Regulatory Role for a Novel Human Thioredoxin Peroxidase in NF-κB Activation*
D. Jin (1997)
Thioredoxin Peroxidase Is a Novel Inhibitor of Apoptosis with a Mechanism Distinct from That of Bcl-2*
Ping Zhang (1997)
Characterization of a Mammalian Peroxiredoxin That Contains One Conserved Cysteine*
S. W. Kang (1998)
Cloning and Characterization of AOEB166, a Novel Mammalian Antioxidant Enzyme of the Peroxiredoxin Family*
B. Knoops (1999)
Characterization of Human and Murine PMP20 Peroxisomal Proteins That Exhibit Antioxidant Activity in Vitro *
H. Yamashita (1999)
Peroxiredoxin I expression in human thyroid tumors.
T. Yanagawa (1999)
Role of Peroxiredoxins in Regulating Intracellular Hydrogen Peroxide and Hydrogen Peroxide-induced Apoptosis in Thyroid Cells*
H. Kim (2000)
Peroxiredoxin is ubiquitously expressed in rat skin: isotype-specific expression in the epidermis and hair follicle.
S. Lee (2000)
Peroxiredoxin I expression in oral cancer: a potential new tumor marker.
T. Yanagawa (2000)
Identification of a New Type of Mammalian Peroxiredoxin That Forms an Intramolecular Disulfide as a Reaction Intermediate*
M. S. Seo (2000)
Antisense of human peroxiredoxin II enhances radiation-induced cell death.
S. Park (2000)
Augmented expression of peroxiredoxin I in lung cancer.
J. Chang (2001)
Synergistic effect of peroxiredoxin II antisense on cisplatin-induced cell death
Y. Yoo (2002)
Proteomics Analysis of Cellular Response to Oxidative Stress
T. Rabilloud (2002)
Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma
V. Kinnula (2002)
Nonredundant Antioxidant Defense by Multiple Two-Cysteine Peroxiredoxins in Human Prostate Cancer Cells
C. Shen (2002)
Peroxiredoxins in breast carcinoma.
P. Karihtala (2003)
Phorbol Ester-dependent Activation of Peroxiredoxin I Gene Expression via a Protein Kinase C, Ras, p38 Mitogen-activated Protein Kinase Signaling Pathway*
A. Hess (2003)
Oxidative stress in viral and alcoholic hepatitis.
C. Loguercio (2003)
Protein Expression Profiles in Pancreatic Adenocarcinoma Compared with Normal Pancreatic Tissue and Tissue Affected by Pancreatitis as Detected by Two-Dimensional Gel Electrophoresis and Mass Spectrometry
Jianjun Shen (2004)
The differential proteome profile of stomach cancer: identification of the biomarker candidates.
J. S. Jang (2004)
ROS stress in cancer cells and therapeutic implications.
H. Pelicano (2004)
Prediction of Docetaxel Response in Human Breast Cancer by Gene Expression Profiling
J. C. Chang (2005)
Identification of differentially expressed proteins during human urinary bladder cancer progression.
A. Memon (2005)
Comparative proteomic analysis of esophageal squamous cell carcinoma
Y. Qi (2005)
Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling.
S. Rhee (2005)
The global health burden of infection‐associated cancers in the year 2002
D. Parkin (2006)
Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression.
M. Chen (2006)
Increased etheno-DNA adducts in affected tissues of patients suffering from Crohn's disease, ulcerative colitis, and chronic pancreatitis.
J. Nair (2006)
Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis
J. Lin (2007)
Proteomic profiling of endothelial cells in human lung cancer.
Hye-jeong Park (2008)
Oxidative stress in ulcerative colitis-associated carcinogenesis.
A. Roessner (2008)
Comparative Proteomic Analysis of Osteosarcoma Cell and Human Primary Cultured Osteoblastic Cell
X. Liu (2009)
This paper is referenced by
The critical role of peroxiredoxin-2 in colon cancer stem cells
Linglong Peng (2021)
Peroxiredoxins and Immune Infiltrations in Colon Adenocarcinoma: Their Negative Correlations and Clinical Significances, an In Silico Analysis
Xiuzhi Zhang (2020)
Upregulation of Peroxiredoxin-2 in Well-Differentiated Pancreatic Neuroendocrine Tumors and Its Utility as a Biomarker for Predicting the Response to Everolimus
E. Kim (2020)
Prdx2 Upregulation Promotes the Growth and Survival of Gastric Cancer Cells
Shouru Zhang (2019)
Catalytic and Signaling Role of Peroxiredoxins in Carcinogenesis
M. Sharapov (2019)
Peroxiredoxins in Colorectal Cancer: Predictive Biomarkers of Radiation Response and Therapeutic Targets to Increase Radiation Sensitivity?
J. Fischer (2018)
The prognostic values of the peroxiredoxins family in ovarian cancer
Peroxiredoxin II Regulates Cancer Stem Cells and Stemness-Associated Properties of Cancers
Nisansala Chandimali (2018)
Peroxiredoxin Involvement in the Initiation and Progression of Human Cancer.
M. Hampton (2017)
Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K/AKT signaling pathway
Jun Xu (2017)
Peroxiredoxin 2 is associated with colorectal cancer progression and poor survival of patients
Linglong Peng (2017)
The application of proteomics in different aspects of hepatocellular carcinoma research.
Xiaohua Xing (2016)
Peroxiredoxin 2 is essential for maintaining cancer stem cell-like phenotype through activation of Hedgehog signaling pathway in colon cancer
Rong Wang (2016)
Overexpression of Prdx1 in hilar cholangiocarcinoma: a predictor for recurrence and prognosis.
J. Zhou (2015)
Plasma nuclear factor kappa B and serum peroxiredoxin 3 in early diagnosis of hepatocellular carcinoma.
S. Ismail (2015)
The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells
Lianqin Li (2015)
Serum peroxiredoxin3 is a useful biomarker for early diagnosis and assessemnt of prognosis of hepatocellular carcinoma in Chinese patients.
L. Shi (2014)
Peroxiredoxin 2 knockdown by RNA interference inhibits the growth of colorectal cancer cells by downregulating Wnt/β-catenin signaling.
Weidong Lu (2014)
Proteomic Characterization of Acyclovir-Induced Nephrotoxicity in a Mouse Model
Hong Lu (2014)
Proteomic analysis of non-small cell lung cancer tissue interstitial fluids
Shaomin Li (2013)
Peroxiredoxin 2 is upregulated in colorectal cancer and contributes to colorectal cancer cells’ survival by protecting cells from oxidative stress
Weidong Lu (2014)
Thioredoxins, glutaredoxins, and peroxiredoxins--molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling.
E. Hanschmann (2013)
Peroxiredoxin 3 is resistant to oxidation-induced apoptosis of Hep-3b cells
Y-G Wang (2014)
Expression and prognostic significance of human peroxiredoxin isoforms in endometrial cancer.
Seulhee Han (2012)
Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma.
Ponlapat Yonglitthipagon (2012)
Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach.
B. Qiao (2012)
Proteomic Analysis of Ovarian Cancer Proximal Fluids: Validation of Elevated Peroxiredoxin 1 in Patient Peripheral Circulation
E. Hoskins (2011)